These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

215 related items for PubMed ID: 18991331

  • 1. E2Fs mediate a fundamental cell-cycle deregulation in high-grade serous ovarian carcinomas.
    De Meyer T, Bijsmans IT, Van de Vijver KK, Bekaert S, Oosting J, Van Criekinge W, van Engeland M, Sieben NL.
    J Pathol; 2009 Jan; 217(1):14-20. PubMed ID: 18991331
    [Abstract] [Full Text] [Related]

  • 2. Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy.
    Bignotti E, Tassi RA, Calza S, Ravaggi A, Romani C, Rossi E, Falchetti M, Odicino FE, Pecorelli S, Santin AD.
    Gynecol Oncol; 2006 Nov; 103(2):405-16. PubMed ID: 16725184
    [Abstract] [Full Text] [Related]

  • 3. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.
    Bonome T, Lee JY, Park DC, Radonovich M, Pise-Masison C, Brady J, Gardner GJ, Hao K, Wong WH, Barrett JC, Lu KH, Sood AK, Gershenson DM, Mok SC, Birrer MJ.
    Cancer Res; 2005 Nov 15; 65(22):10602-12. PubMed ID: 16288054
    [Abstract] [Full Text] [Related]

  • 4. Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential.
    Meinhold-Heerlein I, Bauerschlag D, Hilpert F, Dimitrov P, Sapinoso LM, Orlowska-Volk M, Bauknecht T, Park TW, Jonat W, Jacobsen A, Sehouli J, Luttges J, Krajewski M, Krajewski S, Reed JC, Arnold N, Hampton GM.
    Oncogene; 2005 Feb 03; 24(6):1053-65. PubMed ID: 15558012
    [Abstract] [Full Text] [Related]

  • 5. Expression of the E2F family of transcription factors and its clinical relevance in ovarian cancer.
    Reimer D, Sadr S, Wiedemair A, Goebel G, Concin N, Hofstetter G, Marth C, Zeimet AG.
    Ann N Y Acad Sci; 2006 Dec 03; 1091():270-81. PubMed ID: 17341621
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Immunohistochemical overexpression of p16 and p53 in uterine serous carcinoma and ovarian high-grade serous carcinoma.
    Chiesa-Vottero AG, Malpica A, Deavers MT, Broaddus R, Nuovo GJ, Silva EG.
    Int J Gynecol Pathol; 2007 Jul 03; 26(3):328-33. PubMed ID: 17581420
    [Abstract] [Full Text] [Related]

  • 11. Histologic type, organ of origin, and Wnt pathway status: effect on gene expression in ovarian and uterine carcinomas.
    Shedden KA, Kshirsagar MP, Schwartz DR, Wu R, Yu H, Misek DE, Hanash S, Katabuchi H, Ellenson LH, Fearon ER, Cho KR.
    Clin Cancer Res; 2005 Mar 15; 11(6):2123-31. PubMed ID: 15788657
    [Abstract] [Full Text] [Related]

  • 12. Coordinately up-regulated genes in ovarian cancer.
    Hough CD, Cho KR, Zonderman AB, Schwartz DR, Morin PJ.
    Cancer Res; 2001 May 15; 61(10):3869-76. PubMed ID: 11358798
    [Abstract] [Full Text] [Related]

  • 13. High insulin-like growth factor-2 (IGF-2) gene expression is an independent predictor of poor survival for patients with advanced stage serous epithelial ovarian cancer.
    Sayer RA, Lancaster JM, Pittman J, Gray J, Whitaker R, Marks JR, Berchuck A.
    Gynecol Oncol; 2005 Feb 15; 96(2):355-61. PubMed ID: 15661221
    [Abstract] [Full Text] [Related]

  • 14. Gene expression profiles of luteal phase fallopian tube epithelium from BRCA mutation carriers resemble high-grade serous carcinoma.
    Tone AA, Begley H, Sharma M, Murphy J, Rosen B, Brown TJ, Shaw PA.
    Clin Cancer Res; 2008 Jul 01; 14(13):4067-78. PubMed ID: 18593983
    [Abstract] [Full Text] [Related]

  • 15. Clinical relevance of E2F family members in ovarian cancer--an evaluation in a training set of 77 patients.
    Reimer D, Sadr S, Wiedemair A, Stadlmann S, Concin N, Hofstetter G, Müller-Holzner E, Marth C, Zeimet AG.
    Clin Cancer Res; 2007 Jan 01; 13(1):144-51. PubMed ID: 17200349
    [Abstract] [Full Text] [Related]

  • 16. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.
    Yanagie H, Hisa T, Ogata A, Miyazaki A, Nonaka Y, Nishihira T, Osada I, Sairennji T, Sugiyama H, Furuya Y, Kidani Y, Takamoto S, Takahashi H, Eriguchi M.
    Biomed Pharmacother; 2009 Sep 01; 63(8):553-60. PubMed ID: 18571892
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Expression and significance of microRNAs in the p53 pathway in ovarian cancer cells and serous ovarian cancer tissues].
    Zhang Q, He XJ, Ma LP, Li N, Yang J, Cheng YX, Cui H.
    Zhonghua Zhong Liu Za Zhi; 2011 Dec 01; 33(12):885-90. PubMed ID: 22340095
    [Abstract] [Full Text] [Related]

  • 19. Identification of novel E2F1 target genes regulated in cell cycle-dependent and independent manners.
    Iwanaga R, Komori H, Ishida S, Okamura N, Nakayama K, Nakayama KI, Ohtani K.
    Oncogene; 2006 Mar 16; 25(12):1786-98. PubMed ID: 16288221
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.